<DOC>
	<DOCNO>NCT01998035</DOCNO>
	<brief_summary>This open label , phase I/IIa , 3 x 3 dose escalation study initial phase I follow disease focus phase II . The primary objective phase I determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) combination oral 5-azacitidine romidepsin patient lymphoma . The safety toxicity combination evaluate throughout entire study . If combination oral 5-azacitidine romidepsin find feasible MTD establish , phase II part study initiate . Phase II consist 2 stage design combination oral 5-azacitidine romidepsin patient relapse refractory T-cell lymphoma .</brief_summary>
	<brief_title>Romidepsin Plus Oral 5-Azacitidine Relapsed/Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>Subjects receive oral 5-azacitidine romidepsin , administer follow : oral 5-azacitidine Days 1-14 ( Dose cohort -1 5 ) Days 1-21 ( Dose cohort 6 ) ; romidepsin administer intravenously Days 8 ( Dose cohorts 1-4 ) 28 day cycle , Day 22 ( Dose cohorts 5 6 ) 35 day cycle . Cohorts 3 patient enrol sequentially outline dose escalation scheme . Once MTD reach Phase II part protocol initiated patient T-Cell Lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Phase I : Histologically confirm relapsed refractory nonHodgkin lymphoma Hodgkin lymphoma ( WHO criteria ) , accept curative option . Phase II : Relapsed refractory Tcell lymphoma , include patient central nervous system ( CNS ) involvement lymphomatous meningitis allow study . Relapsed refractory disease follow frontline chemotherapy . No upper limit number prior therapy . Patients may relapse prior autologous allogeneic stem cell transplant . Evaluable Disease Phase I , measurable disease Phase II . Age &gt; = 18 year . ECOG performance status &lt; = 2 . Patients must adequate organ marrow function . Negative urine serum pregnancy test female childbearing potential . All female childbearing potential must use effective barrier method contraception treatment period least 1 month thereafter . Male subject use barrier method contraception treatment period least 3 month thereafter . Ability understand willingness sign write informed consent document . Prior Therapy Exposure chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 2 week earlier . Systemic steroid stabilize ( ≥ 5 day ) equivalent ≤10 mg/day prednisone prior start study drug . No concurrent investigational agent allow . History allergic reaction Oral 5azacitidine Romidepsin . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman . Nursing woman . Active concurrent malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) . If history prior malignancy , patient must diseasefree ≥ 3 year . Patients know Human Immunodeficiency Virus ( HIV ) positive . Patients active hepatitis A , hepatitis B , hepatitis C infection . Concomitant use CYP3A4 inhibitor . Any known cardiac abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Non-hodgkin Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
</DOC>